Correction to: Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease.

Copyright de los autores.Alzheimer's disease (AD) is a progressive neurodegenerative disease in which the formation of extracellular aggregates of amyloid beta (Aβ) peptide, fibrillary tangles of intraneuronal tau and microglial activation are major pathological hallmarks. One of the key molecules involved in microglial activation is galectin-3 (gal3), and we demonstrate here for the first time a key role of gal3 in AD pathology. Gal3 was highly upregulated in the brains of AD patients and 5xFAD (familial Alzheimer's disease) mice and found specifically expressed in microglia associated with Aβ plaques. Single-nucleotide polymorphisms in the LGALS3 gene, which encodes gal3, were associated with an increased risk of AD. Gal3 deletion in 5xFAD mice attenuated microglia-associated immune responses, particularly those associated with TLR and TREM2/DAP12 signaling. In vitro data revealed that gal3 was required to fully activate microglia in response to fibrillar Aβ. Gal3 deletion decreased the Aβ burden in 5xFAD mice and improved cognitive behavior. Interestingly, a single intrahippocampal injection of gal3 along with Aβ monomers in WT mice was sufficient to induce the formation of long-lasting (2 months) insoluble Aβ aggregates, which were absent when gal3 was lacking. High-resolution microscopy (stochastic optical reconstruction microscopy) demonstrated close colocalization of gal3 and TREM2 in microglial processes, and a direct interaction was shown by a fluorescence anisotropy assay involving the gal3 carbohydrate recognition domain. Furthermore, gal3 was shown to stimulate TREM2-DAP12 signaling in a reporter cell line. Overall, our data support the view that gal3 inhibition may be a potential pharmacological approach to counteract AD.- Financiación del Consejo de Investigación Sueca, y el Parque de Investigación "Strong Research Environment MultiPark (Multidisciplinary Research in Parkinson’s and Alzheimer’s Disease" de la Universidad de Lund. - Bagadilico (consorciado esponsorizado por el Consejo de Investigación Sueca), la Fundación Sueca de Alzheimer, la fundación Sueca del Cerebro, Fundación A.E. Berger Foundation, la fundación Gyllenstiernska Krapperup, la Real Sociedad Fisiográfica, la Fundación Crafoord, Fundación Olle Engkvist Byggmästare, Fundación Wiberg, Fundación G&J Kock, Fundación Stohnes, Asociación Sueca de Demencia y la Facultad de Medicina de la Universidad de Lund. - Proyectos SAF2015-64171R (MINECO/FEDER, UE) - Instituto de Salud Carlos III (ISCiii) co-financiado por fondos FEDER de la Unión Europea por proyectos PI15/00796 y PI18/01557 (a AG), PI15/00957 y PI18/01556 (JV). - CIBERNED “Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid (AG y JV) - Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía Proyecto de Excelencia (CTS2035) (JV y AG). - Universidad de Málaga referencia PPIT.UMA.27(RSV) - AV y GCB recibieron fondos de la Iniciativa para Medicina Innovativa ref. 115976 (PHAGO). - Consejo de Investigación Sueca, Fundación Sueca del Cerebro, Fundación de Alzheimer y Fundación Ahlen (a HL y AF). - Proyecto de Fundación Knut and Alice Wallenberg (UJN) (KAW 2013.0022) y Consejo de Investigación Sueca (ref. 621-2012-2978)

Brain pericytes acquire a microglial phenotype after stroke.

Pericytes are located on the abluminal side of endothelial cells lining the microvasculature in all organs. They have been identified as multipotent progenitor cells in several tissues of the body including the human brain. New evidence suggests that pericytes contribute to tissue repair, but their role in the injured brain is largely unknown. Here, we investigate the role of pericytes in ischemic stroke. Using a pericyte-reporter mouse model, we provide unique evidence that regulator of G-protein signaling 5 expressing cells are activated pericytes that leave the blood vessel wall, proliferate and give rise to microglial cells after ischemic brain injury. Consistently, we show that activated pericytes express microglial markers in human stroke brain tissue. We demonstrate that human brain-derived pericytes adopt a microglial phenotype and upregulate mRNA specific for activated microglial cells under hypoxic conditions in vitro. Our study indicates that the vasculature is a novel source of inflammatory cells with a microglial phenotype in brain ischemia and hence identifies pericytes as an important new target for the development of future stroke therapies

Label-free concentration of viable neurons, hESCs and cancer cells by means of acoustophoresis.

Concentration of viable cell populations in suspension is of interest for several clinical and pre-clinical applications. Here, we report that microfluidic acoustophoresis is an effective method to efficiently concentrate live and viable cells with high target purity without any need for protein fluorescent labeling using antibodies or over-expression. We explored the effect of the acoustic field acoustic energy density and systematically used different protocols to induce apoptosis or cell death and then determined the efficiency of live and dead cell separation. We used the breast cancer cell line MCF-7, the mouse neuroblastoma N2a as well as human embryonic stem cells (hESCs) to demonstrate that this method is gentle and can be applied to different cell populations. First, we induced cell death by means of high osmotic shock using a high concentration of PBS (10×), the protein kinase inhibitor staurosporine, high concentrations of dimethyl sulfoxide (DMSO, 10%), and finally, cell starvation. In all the methods employed, we successfully induced cell death and were able to purify and concentrate the remaining live cells using acoustophoresis. Importantly, the concentration of viable cells was not dependent on a specific cell type. Further, we demonstrate that different death inducing stimuli have different effects on the intrinsic cell properties and therefore affect the efficiency of the acoustophoretic separation

Microchannel acoustophoresis does not impact survival or function of microglia, leukocytes or tumor cells.

The use of acoustic forces to manipulate particles or cells at the microfluidic scale (i.e. acoustophoresis), enables non-contact, label-free separation based on intrinsic cell properties such as size, density and compressibility. Acoustophoresis holds great promise as a cell separation technique in several research and clinical areas. However, it has been suggested that the force acting upon cells undergoing acoustophoresis may impact cell viability, proliferation or cell function via subtle phenotypic changes. If this were the case, it would suggest that the acoustophoresis method would be a less useful tool for many cell analysis applications as well as for cell therapy.We investigate, for the first time, several key aspects of cellular changes following acoustophoretic processing. We used two settings of ultrasonic actuation, one that is used for cell sorting (10 Vpp operating voltage) and one that is close to the maximum of what the system can generate (20 Vpp). We used microglial cells and assessed cell viability and proliferation, as well as the inflammatory response that is indicative of more subtle changes in cellular phenotype. Furthermore, we adapted a similar methodology to monitor the response of human prostate cancer cells to acoustophoretic processing. Lastly, we analyzed the respiratory properties of human leukocytes and thrombocytes to explore if acoustophoretic processing has adverse effects.BV2 microglia were unaltered after acoustophoretic processing as measured by apoptosis and cell turnover assays as well as inflammatory cytokine response up to 48 h following acoustophoresis. Similarly, we found that acoustophoretic processing neither affected the cell viability of prostate cancer cells nor altered their prostate-specific antigen secretion following androgen receptor activation. Finally, human thrombocytes and leukocytes displayed unaltered mitochondrial respiratory function and integrity after acoustophoretic processing.We conclude that microchannel acoustophoresis can be used for effective continuous flow-based cell separation without affecting cell viability, proliferation, mitochondrial respiration or inflammatory status

Unaltered viability of BV2 microglial cell line following acoustophoretic processing (10V_pp and 20V_pp).

<p>BV2 cells were passed through the acoustophoresis chip with the function generator set at 0, 10 and 20 V_pp. After going through the chip, the BV2 cells were seeded again for 24 and 48 h. Cell viability was measured by XTT (a), apoptotic nuclei appearance (b) and decrease of mitochondrial potential -Ψm- (c), showing no difference between experimental groups. Similar, no difference was detected by clonogenic assay (d) used to study survival and proliferation at 7 days following acoustophoretic processing. The graphs show the results from at least three separate experiments and the data are shown as means ± SD. Significance value <i>P</i><0.05, ns denotes non-significant.</p

Acoustic cell separation in a microchannel does not alter PSA secretion by prostate cancer cells.

<p>The androgen receptor (AR) expressing cell lines LNCaP and VCaP were used to evaluate the impact of acoustophoresis on PSA secretion. After acoustophoresis run at 0, 10 and 20 V_pp, the secretion of PSA was measured in the absence or presence of the AR ligand R1881 (1 nM for 24 h) in the LNCaP cell line (a) and in the VCaP cell line (b). Cells not processed through the chip were used as control cells. The graphs show the results from three separate experiments and the data are shown as means ± SD. Significance value <i>P</i><0.05, ns denotes non-significant.</p

Mitochondrial respiratory function in human leukocytes and thrombocytes are not altered following acoustophoresis.

<p>Leukocytes and thrombocytes were passed through the acoustophoresis chip run at 0, 10 and 20 V_pp. Maximal respiration during using both complex I- and complex II-linked substrates for thrombocytes (a) and leukotcytes (b) was unaltered after acoustophoresis, supporting that acoustophoresis does not affect metabolic pathways important for respiration. The remaining respiratory activity following inhibition of ATP synthase with oligomycin, so called Leak or state 4 respiration, was also unaffected by acoustophoresis, in thrombocytes (c) and leukocytes (d). This data confirm no effect of acoustophoresis on inner mitochondrial membrane integrity or changed utilization of proton motive force for other purposes than ADP phosphorylation. Unprocessed cells were used as control cells. The graphs show the results from three separate experiments and the data are shown as means ± SD. Significance value <i>P</i><0.05, ns denotes non-significant.</p

Picture and illustration of the set up.

<p>(a) Photo of the acoustophoresis microfluidic system first presented by Augustsson <i>et al. </i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0064233#pone.0064233-Augustsson3" target="_blank">[27]</a>. (b) Cross sectional view of cell distribution in the microchannel without ultrasound (left) and with ultrasound forming an ultrasound standing wave (right). (c) Illustration of acouscoustophoresis chip. For the present study, only one of the channel segments was used allowing cells to be exposed to ultrasound.</p

Inflammatory response of BV2 cells upon LPS challenge following acoustophoresis is not changed.

<p>After acoustophoretic processing, BV2 cells were seeded and stimulated the next day with LPS for 24 h. We observed no alteration due to acoustophoretic processing in the expression of iNOS (inducible nitric oxide synthase)(a,b), the release of proinflammatory cytokines IL-1β (χ), IL-12 (d), TNF-α (e) or the anti-inflammatory cytokine IL-10 (f). The graphs show the results from at least three separate experiments and the data are shown as means ± SD. Significance value <i>P</i><0.05, ns denotes non-significant.</p